Ponatinib
|
- ₹0
- Product name: Ponatinib
- CAS: 943319-70-8
- MF: C29H27F3N6O
- MW: 532.56
- EINECS:1308068-626-2
- MDL Number:MFCD17215203
- Synonyms:AP24534(Ponatinib);3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide;AP24534;AP24534;PONATINIB;3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)BENZAMIDE;Ponatinib;3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide;Ponatinib (AP24534);Ponatinib (with 4 ints.)
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :>175°C (dec.)
Density :1.3
storage temp. :-20°C
solubility :Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml with warming).
form :Yellow powder.
pka :12.99±0.70(Predicted)
color :Yellow
Stability :Stable for 2 years from date? of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
CAS DataBase Reference :943319-70-8
Density :1.3
storage temp. :-20°C
solubility :Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 25 mg/ml with warming).
form :Yellow powder.
pka :12.99±0.70(Predicted)
color :Yellow
Stability :Stable for 2 years from date? of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
CAS DataBase Reference :943319-70-8
Safety Information
| Symbol(GHS): |
 
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Danger | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
Ponatinib is an orally available, pan-Bcr-Abl tyrosine kinase inhibitor developed for the treatment of an advanced phase of chronic myeloid leukemia in which mutations of the kinase endow resistance to other Bcr-Abl inhibitors. Ponatinib potently inhibits native Bcr-Abl (IC50 = 0.37 nM) as well as various clinically important mutant forms including Bcr-AblT315I (IC50 = 2 nM). It can also inhibit c-Src (IC50 = 5.4 nM) and VEGFR, FGFR, and PDGFR receptor tyrosine kinases (IC50s = 1-2 nM), yet is >1,000-fold selective against family members of Aurora kinase, insulin receptor kinase, or cyclin-dependent kinase. Ponatinib has been shown to inhibit proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant (IC50s = 0.5-36 nM) Bcr-Abl by inducing apoptosis. In a Ba/F3 Bcr- AblT315I xenograft model, tumor growth was inhibited in mice upon oral dosing at 10-30 mg/kg.Related product price
- Sunitinib Malate
₹15891.1-63477.8 - Dasatinib
₹3702.15-4546.5 - Bortezomib
₹12940
